Chaetocin attenuates atherosclerosis progression and inhibits vascular smooth muscle cell phenotype switching

Area of Science:

• Cardiovascular Research
• Molecular Biology
• Epigenetics

Background:

• Atherosclerosis is a chronic inflammatory disease characterized by plaque buildup in arteries.
• Vascular smooth muscle cells (VSMCs) play a critical role in atherosclerosis progression and plaque stability.
• Understanding the molecular mechanisms regulating VSMC phenotype is crucial for developing new therapies.

Purpose of the Study:

• To investigate the effects of chaetocin on atherosclerosis.
• To elucidate the underlying molecular mechanisms of chaetocin's action on VSMCs.
• To evaluate chaetocin's potential as a therapeutic agent for atherosclerosis.

Main Methods:

• In vitro studies using VSMCs to assess proliferation, migration, and phenotypic switching.
• Analysis of α-SMA, SM22α expression, and H3K9me3 accumulation in VSMCs.
• In vivo studies in an atherosclerosis model to evaluate plaque formation and stability.
• Histological analysis of atherosclerotic plaques, including necrotic core area, lipid content, and collagen deposition.

Main Results:

• Chaetocin inhibited VSMC proliferation and migration in a dose- and time-dependent manner.
• Chaetocin induced a contractile VSMC phenotype by increasing α-SMA and SM22α expression.
• Chaetocin reduced H3K9me3 accumulation on VSMC contractile gene promoters.
• In vivo, chaetocin diminished atherosclerotic plaque formation and enhanced plaque stability.

Conclusions:

• Chaetocin demonstrates a novel function in inhibiting atherosclerosis progression.
• Chaetocin increases plaque stability by preventing pathological VSMC phenotypic switching.
• Chaetocin represents a potential therapeutic target for atherosclerosis treatment.